


The *Beljanski* Foundation

Newsletter

Winter 2006



Columbia University

Dear Friends,

From all of us at the Beljanski Foundation, we wish you and your loved ones a happy and healthy New Year! In 2006, we are pleased to report about a remarkable symposium at Columbia University in New York City. This event was devoted to the work of Mirko Beljanski, as well as to the current development of his research. Doctors and scientists from the United States and Europe gave presentations about the history of our products and the scientific research that supports their use. Preclinical research, clinical trials and numerous case histories were presented. The following is a brief summary of the highlights.

John Hall, PhD, Director of Research at Natural Source International, Ltd., gave an overview of the scientific findings. He explained that 50 years of Mirko Beljanski's research has resulted in the discovery of beneficial dietary supplements, several of which are now the focus of clinical trials. Dr. Hall emphasized the advantages of Professor Beljanski's approach, which differs from mainstream paradigms in biomedical research. While major efforts to explore the primary cause of cancer at the molecular level have focused on identifying mutations in critical genes, Dr. Beljanski discovered that there is a fundamental difference in the physical structure of the DNA isolated from cancer cells and healthy cells: the double helix of cancer cell DNA is destabilized. This result gave Dr. Beljanski a novel way to think about cancer that he exploited in the development of the Pao pereira and Rauwolfia vomitoria extracts.



John Hall,
Director of Research

INTERNATIONAL JOURNAL OF ONCOLOGY 29: 1065-1073, 2006

Anti-prostate cancer activity of a β -carboline alkaloid enriched extract from *Rauwolfia vomitoria*

D.L. BEMIS¹, J.L. CAPODICE¹, P. GORROOCHURN², A.E. KATZ¹ and R. BUTTYAN¹

Debra Bemis, PhD, from the Department of Urology at Columbia University, shared laboratory results showing that the Pao pereira and Rauwolfia vomitoria extracts destroy tumors in vitro and in vivo. Her work established that the mechanisms by which these two extracts eliminate cancerous cells are different and complementary, justifying their use in a parallel manner. The research focusing on the Rauwolfia extract has just been published in the prestigious International Journal of Oncology (D.L. Bemis, J.L. Capodice, P. Gorroochurn, A.E. Katz, and R. Buttyan *Int J Oncol.* 29: 1065-1073, 2006). Another publication on the Pao extract is scheduled to appear next year.

In an exceptional presentation, Aaron Katz, MD, Head of the Department of Holistic Urology at Columbia University, spoke of encouraging preliminary results from a clinical trial using Prostabel[®], a combination of Pao pereira and Rauwolfia vomitoria. A Phase II clinical trial is now being planned.

The *Beljanski* Foundation



Following his presentation, Monique Beljanski presented the first ever *Beljanski Foundation Award* to Dr. Katz and the Urologic Cancer Research Treatment Institute, LLC. The team at Columbia University has done a wonderful job of building on the research of Mirko Beljanski, an effort the Beljanski Foundation was proud to recognize with this award.

Following Dr. Katz, James Grutsch, PhD, discussed the exciting preliminary results observed during the clinical trial at Cancer Treatment Centers of America (CTCA). Dr. Grutsch explained that Beljanski's RNA fragments have the potential to maintain healthy levels of platelets despite aggressive chemotherapy. Dr. Grutsch noted that the preliminary results have been particularly impressive and that a Phase II clinical trial is in the works.



Doctors in Europe are using ReaLBuild[®] with autistic children and the preliminary results are positive. If you or anyone you know is interested in this application, please let us know.



Next, Michael Schachter, MD, from Suffern, NY, presented the importance of a holistic approach to medicine, and the importance of scrutinizing the many pollutants in our environment that contribute to cancer.

In addition to the scientific research presented by the American speakers, several French doctors also participated in the symposium and spoke of their 15 to 20 years of experience with the Beljanski[®] products. Their clinical observations were optimistic and exciting, complementing the scientific analyses of their American counterparts.

We all have a "stake" in supporting the continued growth of these trees, now and into the future!

RESEARCH AND DEVELOPMENT FOR THE CURES OF TOMORROW: HOW YOU CAN HELP

Are you tired of contributing to medical research without ever seeing a result?

The *Beljanski* Foundation, like other, similar organizations, is committed to funding cutting-edge medical research and looks to the public to help fund tomorrow's cures. Your tax-deductible donation to The Beljanski Foundation does not disappear into a blackhole, leaving the donor to wonder in what ways their contribution was applied. Rather, donors are kept up-to-date with an annual newsletter from The Foundation. The newsletter provides a progress report which details preliminary and final results, as they become available, from the specific research projects that donors' funds have gone to support. The *Beljanski* Foundation thereby allows donors to have a window into the world of research.

The *Beljanski* Foundation Inc is a 501(c)(3) non-profit organization. Contributions are tax deductible to the extent allowed by law.
Tax ID: 13-4086570